Evaluating the Safety and Efficacy of the KXL System for Corneal Collagen Cross-Linking in Eyes Having Keratoconus
NCT ID: NCT02638376
Last Updated: 2015-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
66 participants
INTERVENTIONAL
2013-03-31
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Keratoconus (KC) ,
2. Post LASIK ectasia (PLEc)
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Eyes will be assigned into 2 groups:
* Treatment eyes group with KXL
* Control eyes group (fellow eye) The Treatment eyes will be cross linked with the KXL system and the vibeX Rapid Riboflavin, while the control eyes will not receive any treatment.
The safety and efficacy endpoints will be evaluated and compared between the Treatment eye group and the Control eye group.
After 6 months of follow up the KC and PLEc subjects will be offered to treat the control eyes if indicated.
Group 2 (non-randomised controlled combined treatment)
Eyes will be assigned into 2 groups:
* Treatment group with simultaneous KXL and topography-guided transepithelial photorefractive keratectomy(PRK)
* Control eyes group (fellow eye) The Treatment eyes will undergo simultaneous topography-guided PRK and be cross linked with the KXL system and the vibeX Rapid Riboflavin, while the control eyes will not receive any treatment.
The safety and efficacy endpoints will be evaluated and compared between the Treatment eye group and the Control eye group.
After 6 months of follow up the KC and PLEc subjects will be offered to treat the control eyes if indicated.
The concentrations of Riboflavin Ophthalmic Solution will be tested - 0.1% Riboflavin ophthalmic solution
KC Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous treatment or 8 minutes pulse treatment: 1 second on 1 second off.
PLEc Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous treatment or 8 minutes pulse treatment: 1 second on 1 second off..
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
KXL treatment only
0.1% Riboflavin ophthalmic solution (KXL System With vibeX Rapid)
KC Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off.
PLEc Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off.
KXL and topography-guided PRK
simultaneous KXL and topography-guided transepithelial photorefractive keratectomy(PRK)
0.1% Riboflavin ophthalmic solution (KXL System With vibeX Rapid)
KC Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off.
PLEc Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off.
simultaneous KXL and topography-guided transepithelial photorefractive keratectomy(PRK)
The (Partial, Spherically Corrected) Topography-guided Transepithelial PRK Technique. Is performed with WaveLight® EX 500 excimer laser (Alcon Laboratories Inc, Ft Worth, Texas) customized platform.
This software utilizes topographic data from the linked topography device (Topolyzer; Wave- Light GmbH, Erlangen, Germany). The image of the planned surgery is generated by the laser software.
The topography-guided PRK is used to normalize the cornea by reducing irregular astigmatism while treating part of the refractive error. The maximum ablation depth of stromal ablation is set at 50um.
A 6.5-mm, 50-μm phototherapeutic keratectomy (PTK) was performed to remove the corneal epithelium. Partial topography- guided PRK laser treatment was applied. A cellulose sponge soaked in mitomycin C (MMC) 0.02% solution was applied over the ablated tissue for 20 seconds followed by irrigation with 10 mL of chilled balanced salt solution.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
0.1% Riboflavin ophthalmic solution (KXL System With vibeX Rapid)
KC Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off.
PLEc Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off.
simultaneous KXL and topography-guided transepithelial photorefractive keratectomy(PRK)
The (Partial, Spherically Corrected) Topography-guided Transepithelial PRK Technique. Is performed with WaveLight® EX 500 excimer laser (Alcon Laboratories Inc, Ft Worth, Texas) customized platform.
This software utilizes topographic data from the linked topography device (Topolyzer; Wave- Light GmbH, Erlangen, Germany). The image of the planned surgery is generated by the laser software.
The topography-guided PRK is used to normalize the cornea by reducing irregular astigmatism while treating part of the refractive error. The maximum ablation depth of stromal ablation is set at 50um.
A 6.5-mm, 50-μm phototherapeutic keratectomy (PTK) was performed to remove the corneal epithelium. Partial topography- guided PRK laser treatment was applied. A cellulose sponge soaked in mitomycin C (MMC) 0.02% solution was applied over the ablated tissue for 20 seconds followed by irrigation with 10 mL of chilled balanced salt solution.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Sign the informed consent.
3. Willingness and ability to follow all instructions and comply with schedule for follow-up visits;
4. Contact Lens Wearers Only:
Minimum of 3 days
5. For KC subjects:
1. Axial topography consistent with keratoconus(Pentacam )
2. Presence of central or inferior steepening on the Pentacam map;
3. Steepest keratometry (Kmax) value ≥ 47.00 D;
4. May have corneal scarring up to and including CLEK grade 4.0 (any scarring up to a dense/opaque stromal scar consistent with KC)
5. Keratoconus progressing over time ( evidenced by topography changes, visual acuity or refractive changes)
6. For PLEc subjects:
1. Having a diagnosis of corneal ectasia after corneal refractive surgery (e.g., LASIK, PRK, epi-LASIK,LASEK,)
2. Presence of central or inferior steepening on the Pentacam map.
3. Axial topography consistent with corneal ectasia
Exclusion Criteria
2. If female, be pregnant, nursing or planning a pregnancy or have a positive urine pregnancy test at Visit 2 prior to randomization or during the course of the study;
3. For KC and PLEc subjects, corneal pachymetry that is \< 400microns prior to epithelial debridement at the thinnest point measured by Pentacam in the eye to be treated;
4. A history of chemical injury or delayed epithelial healing in the eye(s) to be treated;
5. Patients with nystagmus or any other condition that would prevent a steady gaze during the treatment or other diagnostic tests;
6. Patients with a current condition that, in the investigator's opinion, would interfere with or prolong epithelial healing;
7. Taking Vitamin C (ascorbic acid) supplements within 1 week of the cross-linking treatment,retinoic acid within 6 months of treatment
8. Previous ocular condition (other than refractive error) in the eye to be treated that may predispose the eye for future complications. For example:
8.1. History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, corneal melt, corneal dystrophy, etc.); 8.2. Clinically significant corneal scarring in the cross-linking treatment zone or in the investigator's opinion, will interfere with the cross-linking procedure;
9. For KC subjects 9.1. Eyes which are aphakic; 9.2. Eyes that have the maximum corneal curvature (Kmax), as identified and measured by Pentacam, outside of the central 5mm zone; Note: In addition, the Investigator may exclude or discontinue any subject for any sound medical reason.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Singapore Eye Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lim Li
A/Prof
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Li Lim, MBBS, FRCS
Role: PRINCIPAL_INVESTIGATOR
Singapore National Eye Centre, Singapore Eye Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Singapore National Eye Centre
Singapore, Singapore, Singapore
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Chuan Teck Ang, Diploma
Role: primary
Mohamed Farook Kothubutheen, BSc (Hons)
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R963/72/2012
Identifier Type: -
Identifier Source: org_study_id